Skip to main content

Azt

Volume 227: debated on Friday 2 July 1993

The text on this page has been created from Hansard archive content, it may contain typographical errors.

To ask the Secretary of State for Health if she will make a statement on the use of AZT with HIV-positive patients of different age groups in the national health service.

Zidovudine—AZT—is currently licensed in the United Kingdom and the European Community for use in the following circumstances:

  • —asymptomatic disease in adult patients showing signs of immune suppression ie. CD4 count repeatedly below 200 per cubic millimetre (cumm) or between 500 and 200 and falling rapidly;
  • —early symptomatic HIV disease in adults with CD4 counts below 500 per cubic millimetre:
  • —advanced disease ie. AIDS and AIDS related complex, in adults and children;
  • —HIV related symptoms or asymptomatic disease with markers indicating significant HIV-related immune suppression in children over the age of three months.